QuantumPharm, Inc. (2228) Stock Statistics & Valuation Metrics

QuantumPharm, Inc. has a market cap or net worth of ―. The enterprise value is HK$16.47B.

QuantumPharm, Inc. has 4,019,811,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

QuantumPharm, Inc.’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -16.45%.

The current PE Ratio of QuantumPharm, Inc. is -7.11. QuantumPharm, Inc.’s PEG ratio is 0.15.

In the last 12 months, QuantumPharm, Inc. had revenue of 266.43M and earned -1.52B in profits. Earnings per share was -0.79.

In the last 12 months, operating cash flow was -299.29M and capital expenditures -32.02M, giving a free cash flow of -331.31M billion.

QuantumPharm, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

QuantumPharm, Inc. upcoming earnings date is Mar 28, 2025, TBA Not Confirmed.

QuantumPharm, Inc. as a current ratio of 11.85, with Debt / Equity ratio of 3.75%

In the past 12 months, QuantumPharm, Inc. has paid 0.00 in taxes.

QuantumPharm, Inc. EV to EBITDA ratio is -15.47, with an EV/FCF ratio of -18.19.

QuantumPharm, Inc. has HK$3.39B in cash and marketable securities with ¥163.57M in debt, giving a net cash position of -HK$3.22B billion.

Gross margin is 45.94%, with operating margin of -256.80%, and net profit margin of -569.23%.

The average price target for QuantumPharm, Inc. is HK$7.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy